Second hovercraft glides into Mangalore

Bengaluru, Apr 1: Karnataka Health Minister B Sriramulu on Wednesday said that 200 people, out of 342 from the state who had attended the religious gathering at Markaz building in Delhi's Nizamuddin area, have been quarantined.

"200 people including four from Bengaluru and five from Belgaum, who participated in Tablighi Jamaat (in Delhi's Nizamuddin), have been quarantined. Total 342 people from Karnataka had attended the event," Sriramulu told reporters here.

The gatherings organised by the Tablighi Jamaat at the Markaz building in Nizamuddin came into the spotlight after multiple coronavirus cases were confirmed amongst those who attended the event held in March.
Twenty-four cases were reported from the national capital alone, apart from Telangana, the union territory of Andaman and Nicobar Islands amongst others.

The minister had earlier said that Bengaluru Urban and Mysuru have been identified among the prime 25 COVID-19 hotspots in the country.
Chikkaballapur, since the last fourteen days, has been emerging as another hotspot, according to Sriramulu.

The total number of coronavirus cases in India has risen to 1,637 after 240 new cases were reported in the country, according to the Ministry of Health and Family Welfare, on Wednesday.

The total number of active cases rose to 1466 in the country, while 132 people have been cured and discharged after receiving treatment, as of 9 am.

Bengaluru, Mar 2: The Opposition Congress and the JD(S) members protested in the Karnataka Legislative Assembly on Monday over the BJP leader Basavaraj Patil Yatnal's alleged derogatory remark against veteran freedom fighter H S Doreswamy.

Opposition Leader in the Assembly and former Chief Minister Siddaramaiah, raised the issue, immediately after the obituary reference of sudden demise of former Minister C Chanigappa, and sought permission from the Speaker to raise the issue of Yatnal's outburst in the House stating that the matter of hurling defamatory remark against Gandhian Doreswamy, by Mr Yatnal, was very much serious. However, the treasury bench members protested and urged the Speaker not to allow the matter to discuss as the issue was not in the agenda.

The Speaker, Vishveshwar Hegde Kageri, promised the Congress leader about permitting the issue after the House adopts resolution on the thanksgiving motion for the Governor's address of the joint House recently and asked Chief Minister B S Yediyurappa to continue his reply to the Governor's address.

The opposition Congress and the JD(S) members, protesting the Speaker's action, trooped into the well of the house and raised slogans against the BJP government.

The Chief Minister continued his reply amidst the din before the Speaker adjourned the House for 30 minutes after the House adopted the thanksgiving motion to the Governor's Address.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.